Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.108
Neutral
RSI(14)
45.110
Neutral
STOCH(KDJ)(9,3,3)
17.917
Sell
ATR(14)
0.387
High Vlolatility
CCI(14)
-64.039
Neutral
Williams %R
74.534
Sell
TRIX(12,20)
0.449
Sell
StochRSI(14)
0.000
Oversold
Search
Ardelyx Inc
ARDXAdd to Watchlist
6.230USD
-0.230-3.56%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.52BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Ardelyx Inc
Currency: USD Updated: 2026-05-15Key Insights
Ardelyx Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 16.07.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ardelyx Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Ardelyx Inc Highlights
StrengthsRisks
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 227.28% year-on-year.
Fairly Valued
The company’s latest PE is -26.39, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 176.00M shares, decreasing 6.41% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 69.48K shares of this stock.
Analyst Rating
Based on
11
analysts
Strong Buy
Current Rating
16.070
Target Price
+151.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Ardelyx Inc is 7.08, ranking 127 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 94.47M, representing a year-over-year increase of 27.47%, while its net profit experienced a year-over-year increase of 8.60%.
Score
Financials
5.60
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.73
Operational Efficiency
10.00
Growth Potential
9.52
Shareholder Returns
7.54
Ardelyx Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Ardelyx Inc is 7.93, ranking 72 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -26.39, which is -76.02% below the recent high of -6.33 and -269.78% above the recent low of -97.58.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 32/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Ardelyx Inc is 9.33, ranking 7 out of 382 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Strong Buy
Current Rating
16.070
Target Price
+148.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ardelyx Inc
ARDX
11
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Ardelyx Inc is 6.92, ranking 125 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.17 and the support level at 5.56, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.458
Sell
MA10
6.758
Sell
MA20
6.447
Sell
MA50
6.119
Buy
MA100
6.474
Sell
MA200
6.092
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Ardelyx Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.25%, representing a quarter-over-quarter decrease of 7.13%. The largest institutional shareholder is James Simons, holding a total of 1.27M shares, representing 0.52% of shares outstanding, with 8.82% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ardelyx Inc is 5.22, ranking 49 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.60
VaR
+6.47%
240-Day Maximum Drawdown
+33.54%
240-Day Volatility
+62.75%
Return
Best Daily Return
60 days
+14.09%
120 days
+20.07%
5 years
+40.98%
Worst Daily Return
60 days
-14.99%
120 days
-14.99%
5 years
-30.25%
Sharpe Ratio
60 days
-0.18
120 days
+0.67
5 years
+0.73
Risk Assessment
Maximum Drawdown
240 days
+33.54%
3 years
+66.32%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+1.84
3 years
+0.45
5 years
+0.58
Skewness
240 days
+1.67
3 years
+0.53
5 years
+1.45
Volatility
Realised Volatility
240 days
+62.75%
5 years
--
Standardised True Range
240 days
+4.69%
5 years
+4.12%
Downside Risk-Adjusted Return
120 days
+119.25%
240 days
+119.25%
Maximum Daily Upside Volatility
60 days
+49.31%
Maximum Daily Downside Volatility
60 days
+48.58%
Liquidity
Average Turnover Rate
60 days
+1.68%
120 days
+1.69%
5 years
--
Turnover Deviation
20 days
+2.12%
60 days
-6.37%
120 days
-5.41%
Peer Comparison
Biotechnology & Medical Research
Ardelyx Inc
ARDX
7.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
